Friday, January 22, 2021
Literary Reviews
  • Home
  • OUR BOOK SHOP
    • Erotic Novels
    • BEST SELLING BOOKS
    • Science Fiction Books
    • Business and Management
    • Computing and IT
    • Cooking
    • Education
    • Religion & Spirituality
    • Self Help
    • Teens & Young Adults
  • Literary Review
  • Literature
  • Book Writing
  • Kindle Publishing
  • Romantic
  • Science Fiction
  • Cooking
  • MORE
    • Erotic
    • Mysteries, Thrillers
    • Literary Themes
    • Business and Management
    • Literary Agents
    • Literary Devices
    • New Books
    • Self Help
    • Teens & Young Adults Novels
    • Computing and IT
    • Education
    • Religion & Spirituality Novels
No Result
View All Result
Literary Reviews
Home Business and Management

New Interim Results from Phase IIIb Study Reinforce the Long-Term Safety Profile of Chugai’s Hemlibra in Hemophilia A

admin by admin
July 13, 2020
in Business and Management
0
New Interim Results from Phase IIIb Study Reinforce the Long-Term Safety Profile of Chugai’s Hemlibra in Hemophilia A
0
SHARES
1
VIEWS
Share on FacebookShare on Twitter

Related posts

COVID-19 Response Services — Occupational Health & Safety

COVID-19 Response Services — Occupational Health & Safety

January 22, 2021
Graco Launches Highest-Powered Electrostatic Airless Disinfectant Sprayer

Graco Launches Highest-Powered Electrostatic Airless Disinfectant Sprayer

January 21, 2021


TOKYO–(BUSINESS WIRE)–Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the second interim analysis results from the phase IIIb STASEY study reinforce the safety profile of Hemlibra® (emicizumab) characterized in the phase III HAVEN studies1,2,3. In the STASEY study, Hemlibra was effective with no new safety signals identified in adults and adolescents with hemophilia A with factor VIII inhibitors, which was consistent with the previously reported safety profile1. The results also suggested people on Hemlibra may be able to undergo certain minor surgeries without additional preventive coagulation factor4. These results were presented at the International Society on Thrombosis and Hemostasis (ISTH) 2020 Virtual Congress (July 12 to 14, 2020).

“I am pleased that the large clinical study data reinforce the long-term safety and tolerability of Hemlibra for the treatment of hemophilia A with inhibitors. The long-term data will provide great clinical insights for treatment with Hemlibra,” said Dr. Osamu Okuda, Chugai’s President and COO. “Hemlibra is a bispecific antibody drug with a novel mechanism of action, clearly distinct from existing drugs. We will continue our efforts to collect and report clinical data so that people with hemophilia A globally can continue to use Hemlibra with confidence.”

The second interim analysis of the STASEY study included data from 193 participants with hemophilia A with factor VIII inhibitors, who received Hemlibra prophylaxis once-weekly1. No cases of thrombotic microangiopathy (TMA) or serious thrombotic events (TEs) related to Hemlibra were reported, and no new safety signals were observed1. Thirty-three (17.1%) people reported a Hemlibra-related adverse event (AE) 1. The most common AEs, occurring in 10% or more of people in the STASEY study, were common cold symptom nasopharyngitis (12.4%), headache (11.9%), and injection-site reaction (ISR) (11.4%)1. The ISRs reported were either mild or moderate in severity and no patients discontinued due to ISR1. Annualized bleed rates (ABR) were also consistent with previously reported observations from the phase III HAVEN studies1,2,3.

A separate analysis described management and outcomes of minor and unplanned major surgeries in patients receiving Hemlibra, although not a formal surgery endpoint in STASEY. Results suggest people with hemophilia A with factor VIII inhibitors who undergo certain minor surgeries whilst receiving Hemlibra may not need additional preventative coagulation factor4. The majority of minor surgeries (n=20/31, 64.5%) were performed without the use of preventative coagulation factor and, of these, 85% (n=17/20) did not result in treated post-operative bleeds4. Of the unplanned major surgeries (n=9), eight were managed with prophylactic coagulation factor, four of which resulted in bleeds managed successfully with recombinant factor VIIa4. These findings are consistent with results observed in a previous analysis of surgeries in the pivotal HAVEN studies5.

STASEY is a single-arm, multicenter, open-label, phase IIIb clinical study where participants received Hemlibra for an average of 50.9 weeks. The ABR of all bleeds, including treated bleeds, treated spontaneous bleeds, treated joint bleeds and treated target joint bleeds were low, with 167 patients (85.6%) experiencing zero treated bleeds1. There were two TEs unrelated to Hemlibra reported. One was a ST-elevation myocardial infarction in a person with pre-existing risk factors, which the treating physician assessed as unrelated to Hemlibra1. The second was a hypertrophic clot at the site of a tooth extraction, a known complication of the procedure1.

There is no participation from Japan to the STASEY study.

Trademarks used or mentioned in this release are protected by law.

Sources

  1. Jimenez-Yuste V et al. Second Interim Analysis Results from STASEY Trial: A Single-arm, Multicenter, Open-Label, Phase III Clinical Trial to Evaluates the Safety and Tolerability of Emicizumab Prophylaxis in People with Hemophilia A (PwHA) with FVIII inhibitors. [poster no. PB0958] International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress, 12-14 July, 2020
  2. Oldenburg J et al. Emicizumab Prophylaxis in Hemophilia A with Inhibitors. NEJM 2017; 377:809-818.
  3. Young G et al. Emicizumab prophylaxis provides flexible and effective bleed control in children with hemophilia A with inhibitors: results from the HAVEN 2 study. Blood 2018; 132 (Supplement 1): 632.
  4. Castaman G et al. Surgical Experience from the Phase III STASEY Trial of Emicizumab Prophylaxis in Persons with Hemophilia A (PwHA) with FVIII Inhibitors: Data from the Second Interim Analysis. [poster no: PB0939] International Society on Thrombosis and Haemostasis (ISTH) 2020 Congress, 12-14 July, 2020
  5. Santagostino E et al. Surgical experience from four phase III studies (HAVEN 1–4) of emicizumab in persons with haemophilia A (PwHA) with or without FVIII inhibitors. [OC 60.1], Nurses and Orals Abstracts. Res Pract Thromb Haemost 2019; 3:1-228

 

Tags: ChugaisHemlibraHemophiliaIIIbInterimLongTermPhaseProfileReinforceResultsSafetystudy
Previous Post

Roger Stone: The Ultimate Dirty Trickster, Formed by Watergate and Tempered in New Jersey

Next Post

‘Mexican Gothic’ is a creepy but gripping tale of powerful women » Borneo Bulletin Online

Next Post
‘Mexican Gothic’ is a creepy but gripping tale of powerful women » Borneo Bulletin Online

‘Mexican Gothic’ is a creepy but gripping tale of powerful women » Borneo Bulletin Online

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

RECOMMENDED NEWS

What nobody told me about sleeping with a virgin man “https://www.pulse.ng/” #WomenTeachSexByPulse [ARTICLE]

What nobody told me about sleeping with a virgin man “https://www.pulse.ng/” #WomenTeachSexByPulse [ARTICLE]

3 months ago
Ottawa teen ‘long-hauler’ wants young people to take COVID-19 seriously

Ottawa teen ‘long-hauler’ wants young people to take COVID-19 seriously

4 months ago
Sunless Sea dev unveils Fallen London prequel and “romantic visual novel” Mask of the Rose • Eurogamer.net

Sunless Sea dev unveils Fallen London prequel and “romantic visual novel” Mask of the Rose • Eurogamer.net

4 weeks ago
Everest Medicines Completes Enrollment of Phase 3 Clinical Trial of Xerava™ (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections in China

BioCryst’s Oral Factor D Inhibitor (BCX9930) Shows High Potency and Specificity for Alternative Pathway of Complement

2 months ago

Products

  • Made in India: 130 Simple, Fresh and Flavourful Recipes from One Indian Family £14.99
  • Little Girl Missing: An absolutely unputdownable crime thriller: 1 (DCI Rachel Hart) £8.99
  • Ikigai: The Japanese secret to a long and happy life £9.79
  • The Man Who Solved the Market: How Jim Simons Launched the Quant Revolution SHORTLISTED FOR THE FT & MCKINSEY BUSINESS… £15.12
  • Python Crash Course (2nd Edition): A Hands-On, Project-Based Introduction to Programming £23.38

BROWSE BY CATEGORIES

  • Book Writing
  • Business and Management
  • Computing and IT
  • Cooking Books
  • Education
  • Erotic
  • Kindle Publishing
  • Literary Agents
  • Literary Devices
  • Literary Review
  • Literary Themes
  • Literature
  • Mysteries, Thrillers & Suspense
  • New Books
  • Religion & Spirituality
  • Romantic Novels
  • Science Fiction
  • Self Help

RELATED PRODUCTS

  • When Evil Comes To Play (The Veil Diaries Book 5) £3.56
  • After the End: The powerful, life-affirming novel from the Sunday Times Number One bestselling author £4.50
  • The Fed and Lehman Brothers: Setting the Record Straight on a Financial Disaster (Studies in Macroeconomic History) £15.79
  • WJEC/Eduqas Religious Studies for A Level Year 1 & AS - Philosophy of Religion and Religion and Ethics £20.42
  • Lockdown: the crime thriller that predicted a world in quarantine £5.00

PRODUCT CATEGORIES

  • Best Selling Books
  • Erotic
  • Science Fiction Books
  • Cooking
  • Business and Management
  • Education
  • Computing and IT
  • Religion & Spirituality
  • Teens & Young Adults
  • Self Help
  • Mysteries, Thrillers & Suspense
  • Romance Books
Literary Reviews

Follow us on social media:

Recent News

  • 25 Romantic Lesbian Love Quotes
  • A Literary Trailblazer’s Solitary Death: Charles Saunders, 73
  • From Terminator 2 to Clue: 10 of the best alternative movie endings | Film

Category

  • Book Writing
  • Business and Management
  • Computing and IT
  • Cooking Books
  • Education
  • Erotic
  • Kindle Publishing
  • Literary Agents
  • Literary Devices
  • Literary Review
  • Literary Themes
  • Literature
  • Mysteries, Thrillers & Suspense
  • New Books
  • Religion & Spirituality
  • Romantic Novels
  • Science Fiction
  • Self Help

Recent News

25 Romantic Lesbian Love Quotes

25 Romantic Lesbian Love Quotes

January 22, 2021
A Literary Trailblazer’s Solitary Death: Charles Saunders, 73

A Literary Trailblazer’s Solitary Death: Charles Saunders, 73

January 22, 2021
  • Home
  • OUR BOOK SHOP
  • Literary Review
  • Literature
  • Book Writing
  • Kindle Publishing
  • Romantic
  • Science Fiction
  • Cooking
  • MORE

© 2020 literaryreviews

No Result
View All Result
  • Home
  • OUR BOOK SHOP
    • Erotic Novels
    • BEST SELLING BOOKS
    • Science Fiction Books
    • Business and Management
    • Computing and IT
    • Cooking
    • Education
    • Religion & Spirituality
    • Self Help
    • Teens & Young Adults
  • Literary Review
  • Literature
  • Book Writing
  • Kindle Publishing
  • Romantic
  • Science Fiction
  • Cooking
  • MORE
    • Erotic
    • Mysteries, Thrillers
    • Literary Themes
    • Business and Management
    • Literary Agents
    • Literary Devices
    • New Books
    • Self Help
    • Teens & Young Adults Novels
    • Computing and IT
    • Education
    • Religion & Spirituality Novels

© 2020 literaryreviews

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In